Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis

Siegel, 2018, Cancer statistics, 2018, CA Cancer J Clin, 68, 7, 10.3322/caac.21442

Ost, 2015, Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature, Eur Urol, 67, 852, 10.1016/j.eururo.2014.09.004

Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853

Siva, 2018, Stereotactic ablative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial, Eur Urol, 74, 455, 10.1016/j.eururo.2018.06.004

Ploussard, 2019, Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review, Eur Urol, 76, 493, 10.1016/j.eururo.2018.10.041

Maurer, 2016, Current use of PSMA-PET in prostate cancer management, Nat Rev Urol, 13, 226, 10.1038/nrurol.2016.26

Silver, 1997, Prostate-specific membrane antigen expression in normal and malignant human tissues, Clin Cancer Res, 3, 81

Bostwick, 1998, Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases, Cancer, 82, 2256, 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S

Afshar-Oromieh, 2013, PET imaging with a [Ga-68]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions, Eur J Nucl Med Mol Imaging, 40, 486, 10.1007/s00259-012-2298-2

Han, 2018, Impact of (68)Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis, Eur Urol, 74, 179, 10.1016/j.eururo.2018.03.030

Perera, 2016, Sensitivity, specificity, and predictors of positive Ga-68-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis, Eur Urol, 70, 926, 10.1016/j.eururo.2016.06.021

Papa, 2016, Eur Urol, 70, 926, 10.1016/j.eururo.2016.06.021

Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration, BMJ, 339, 2700, 10.1136/bmj.b2700

Higgins, 2008

Whiting, 2011, QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies, Ann Intern Med, 155, 529, 10.7326/0003-4819-155-8-201110180-00009

Nyaga, 2014, a Stata command to perform meta-analysis of binomial data, Arch Public Health, 72, 39, 10.1186/2049-3258-72-39

Barendregt, 2013, Meta-analysis of prevalence, J Epidemiol Commun Health, 67, 974, 10.1136/jech-2013-203104

Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557

Dwamena, 2007

Hofman, 2018, A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol, BJU Int, 122, 783, 10.1111/bju.14374

Hovels, 2008, The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis, Clin Radiol, 63, 387, 10.1016/j.crad.2007.05.022

Evangelista, 2013, Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis, Eur Urol, 63, 1040, 10.1016/j.eururo.2012.09.039

Pfister, 2016, Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with Ga-68-PSMA-HBED-CC than with F-18-fluoroethylcholine PET/CT, Eur J Nucl Med Mol Imaging, 43, 1410, 10.1007/s00259-016-3366-9

Eiber, 2016, Simultaneous Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer, Eur Urol, 70, 829, 10.1016/j.eururo.2015.12.053

Al-Bayati, 2018, Integrated (68)Gallium labelled prostate-specific membrane antigen-11 positron emission tomography/magnetic resonance imaging enhances discriminatory power of multi-parametric prostate magnetic resonance imaging, Urol Int, 100, 164, 10.1159/000484695

Lopci, 2018, 68Ga-PSMA positron emission tomography/computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multiparametric magnetic resonance imaging mpMRI: a prospective observational study, J Urol, 200, 95, 10.1016/j.juro.2018.01.079

Donato, 2019, Improved specificity with (68)Ga PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology, Eur J Nucl Med Mol Imaging, 46, 20, 10.1007/s00259-018-4160-7

Perera, 2016, An update on focal therapy for prostate cancer, Nat Rev Urol, 13, 641, 10.1038/nrurol.2016.177

Murphy, 2017, “Gotta catch ‘em all”, or do we? Pokemet approach to metastatic prostate cancer, Eur Urol, 72, 1, 10.1016/j.eururo.2017.02.036

Zacho, 2018, 68 Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature, Clin Physiol Funct Imaging, 38, 911, 10.1111/cpf.12480

Afaq, 2018, Impact of Ga-68-prostate-specific membrane antigen PET/CT on prostate cancer management, J Nucl Med, 59, 89, 10.2967/jnumed.117.192625

Afshar-Oromieh, 2017, Diagnostic performance of Ga-68-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients, Eur J Nucl Med Mol Imaging, 44, 1258, 10.1007/s00259-017-3711-7

Berliner, 2017, Detection rate of PET/CT in patients with biochemical relapse of prostate cancer using [Ga-68]PSMA I&T and comparison with published data of [Ga-68]PSMA HBED-CC, Eur J Nucl Med Mol Imaging, 44, 670, 10.1007/s00259-016-3572-5

Bluemel, 2016, Impact of Ga-68-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy, EJNMMI Res, 6, 78, 10.1186/s13550-016-0233-4

Budaeus, 2016, Initial experience of Ga-68-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy, Eur Urol, 69, 393, 10.1016/j.eururo.2015.06.010

Byrne, 2018, Delineating sites of failure following post-prostatectomy radiation treatment using Ga-68-PSMA-PET, Radiother Oncol, 126, 244, 10.1016/j.radonc.2017.10.022

Calais, 2018, Potential impact of 68Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning, J Nucl Med, 59, 1714, 10.2967/jnumed.118.209387

Ceci, 2015, Ga-68-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?, Eur J Nucl Med Mol Imaging, 42, 1284, 10.1007/s00259-015-3078-6

Demirkol, 2015, Prostate-specific membrane antigen-based imaging in prostate cancer: impact on clinical decision making process, Prostate, 75, 748, 10.1002/pros.22956

Dewes, 2016, Integration of Ga-68-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study, Radiat Oncol, 11, 73, 10.1186/s13014-016-0646-2

Dietlein, 2015, Comparison of [F-18]DCFPyL and [Ga-68]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer, Mol Imaging Biol, 17, 575, 10.1007/s11307-015-0866-0

Eiber, 2015, Evaluation of hybrid Ga-68-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy, J Nucl Med, 56, 668, 10.2967/jnumed.115.154153

Einspieler, 2017, Detection efficacy of hybrid Ga-68-PSMA ligand PET/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by Phoenix criteria, J Nucl Med, 58, 1081, 10.2967/jnumed.116.184457

Grubmuller, 2018, Staging performance and clinical impact of 68Ga-PSMA 11 ligand PET/MRI for primary diagnosed prostate cancer. Presented at: 33rd Annual European Association of Urology Congress, EAU, Denmark, Eur Urol Suppl, 17, e1313, 10.1016/S1569-9056(18)31753-6

Gupta, 2017, A comparative study of 68Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: an initial experience, World J Nucl Med, 16, 186, 10.4103/1450-1147.207272

Gupta, 2017, Prostate-specific membrane antigen positron emission tomography-computed tomography for prostate cancer: distribution of disease and implications for radiation therapy planning, Int J Radiat Oncol Biol Phys, 99, 701, 10.1016/j.ijrobp.2017.06.2448

Habl, 2017, Ga-68-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: individualized medicine or new standard in salvage treatment, Prostate, 77, 920, 10.1002/pros.23347

Henkenberens, 2018, Patterns of relapse as determined by Ga-68-PSMA ligand PET/CT after radical prostatectomy: importance for tailoring and individualizing treatment, Strahlenther Onkol, 194, 303, 10.1007/s00066-017-1231-9

Hruby, 2017, Delineating biochemical failure with Ga-68-PSMA-PET following definitive external beam radiation treatment for prostate cancer, Radiother Oncol, 122, 99, 10.1016/j.radonc.2016.11.023

Kabasakal, 2017, The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels, Nucl Med Commun, 38, 149, 10.1097/MNM.0000000000000617

Kranzbuhler, 2018, Clinical performance of Ga-68-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy, Eur J Nucl Med Mol Imaging, 45, 20, 10.1007/s00259-017-3850-x

Lake, 2017, Optimal MRI sequences for Ga-68-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer, EJNMMI Res, 7, 77, 10.1186/s13550-017-0327-7

Lengana, 2018, Ga-68-PSMA-HBED-CC PET/CT imaging in black versus white South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study, Nucl Med Commun, 39, 179, 10.1097/MNM.0000000000000791

Maurer, 2015, Preoperative lymph node staging in intermediate to high-risk prostate cancer patients using 68Ga-HBED-PSMA PET hybrid imaging—a patient- and field-based analysis, J Urol, 193, 10.1016/j.juro.2015.02.2118

Meredith, 2016, The use of (68) Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer, BJU Int, 118, 49, 10.1111/bju.13616

Obek, 2017, The accuracy of Ga-68-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer, Eur J Nucl Med Mol Imaging, 44, 1806, 10.1007/s00259-017-3752-y

Roach, 2018, The impact of Ga-68-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study, J Nucl Med, 59, 82, 10.2967/jnumed.117.197160

Sanli, 2017, Relationships between serum PSA levels. Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer, Ann Nucl Med, 31, 709, 10.1007/s12149-017-1207-y

Sachpekidis, 2016, Ga-68-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer, Eur J Nucl Med Mol Imaging, 43, 1288, 10.1007/s00259-015-3302-4

Sahlmann, 2016, Biphasic Ga-68-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma, Eur J Nucl Med Mol Imaging, 43, 898, 10.1007/s00259-015-3251-y

Schmuck, 2017, Comparison of standard and delayed imaging to improve the detection rate of [Ga-68]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer, Eur J Nucl Med Mol Imaging, 44, 960, 10.1007/s00259-017-3669-5

Schwenck, 2017, Comparison of Ga-68-labelled PSMA-11 and C-11-choline in the detection of prostate cancer metastases by PET/CT, Eur J Nucl Med Mol Imaging, 44, 92, 10.1007/s00259-016-3490-6

Sterzing, 2016, Ga-68-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients, Eur J Nucl Med Mol Imaging, 43, 34, 10.1007/s00259-015-3188-1

van Leeuwen, 2016, Ga-68-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment, BJU Int, 117, 732, 10.1111/bju.13397

Van Leeuwen, 2016, Prospective evaluation of 68GA-PSMA positron emission tomography/computerized tomography for preoperative lymph node staging in prostate cancer, Presented at: 2016 Annual Meeting of the American Urological Association, AUA, San Diego, CA, USA, J Urol, 195, e1038

Verburg, 2016, Extent of disease in recurrent prostate cancer determined by [Ga-68]PSMA-HBED-CC PET/CT in relation to PSA levels. PSA doubling time and Gleason score, Eur J Nucl Med Mol Imaging, 43, 397, 10.1007/s00259-015-3240-1

Zhang, 2017, Comparison of Ga-68-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer, J Transl Med, 15, 230, 10.1186/s12967-017-1333-2